乌司他丁用于肿瘤患者肠瘘合并严重腹腔感染疗效观察  

Efficacy of Ulinastatin for Intestinal Fistula and Severe Intra-abdominal Infection in Tumor Patients

作　　者：周东民[1] 叶培军[1] 黄静[1] 安山[1] 冯艳平[1] 

机构地区：[1]河南省肿瘤医院ICU,郑州市450008

出　　处：《医药论坛杂志》2010年第16期41-42,共2页Journal of Medical Forum

摘　　要：目的观察乌司他丁用于肿瘤患者术后肠瘘合并发严重腹腔感染的临床效果。方法将54例我院肠瘘合并严重腹腔感染患者随机分为对照组(27例)和治疗组(27例),对照组给予常规治疗,治疗组给于常规治疗基础上,加用乌司他丁900 000-1 200 000U/d,持续静脉泵入,连用7d。比较两组入住ICU天数及死亡率差异;动态观察两组患者第1、4、7d血浆内乳酸、C-反应蛋白、IL-1及IL-6的变化。结果治疗组较对照组的入住ICU天数(18.6±6.2)d vs(24.2±5.7)d缩短及死亡率(22.2%vs 37.0%)下降;治疗组第4、7天血乳酸、C-反应蛋白、IL-1及IL-6水平较对照组下降明显(P<0.05)。结论乌司他丁用于肿瘤患者肠瘘合并严重腹腔感染治疗抗炎效果明显。Objective To evaluate the effect of ulinastatin for intestinal fistula and severe intra-abdominal infection after surgery in tumor patients.Methods Fifty-four tumor patients were divided into two groups： control group（n=27） and treat ment group（n=27）.Patients accepted the conventional therapy in control group and ulinastation was given by intravenous for seven days besides the conventional therapy in the other group.Days in ICU and mortality were compared and the change of lactic acid,C-reactive protein,IL-1 and IL-6 in plasma were observed at the first,fourth and seventh day.Results Days in ICU were short（18.6±6.2d） vs（24.2±5.7 d） and mortality was decreased（22.2% vs 37.0%） significantly in ulinastatin group（P0.05）.Lactic acid,C-reactive protein,IL-1 and IL-6 in plasma were significantly decreased in ulinastatin group（P0.05）.Conclusion Ulinastatin has obvious anti-inflammatory effect for intestinal fistula and severe intra-abdominal infection in tumor patients.

关 键 词：乌司他丁 肿瘤 肠瘘 腹腔感染 

分 类 号：R730.6[医药卫生—肿瘤]